Reported results
- Net loss was $11.3 million for the three months ended September 30, 2026, compared to $8.6 million for the same period in 2025.
- Research and development expenses were $9.2 million for the three months ended September 30, 2026, compared to $6.4 million for the same period in 2025.
- General and administrative expenses were $2.4 million for the three months ended September 30, 2026, compared to $2.6 million for the same period in 2025.
- Cash, cash equivalents and short-term investments were $34.9 million as of September 30, 2026.
- Net cash used in operating activities for the nine months ended September 30, 2026 was $26.0 million compared to $21.3 million for the same period in 2025.
Guidance
- The Company anticipates its current cash, cash equivalents and short-term investments will enable the Company to fund its planned clinical studies and support corporate operations into Q4, 2027.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.
